Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting
Tweet
Share
E-mailGet Alerts CRIS Hot Sheet
Up)Join SI Premium – FREE
LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.
In addition, data will be presented from clinical studies of Erivedge®, a first-in-class drug approved for the treatment of patients with advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.
Additional information on the presentations can be found below and abstracts can be accessed at www.asco.org.
| CUDC-907 Poster Presentation: | ||||||
| Date/Time: | Monday, June 6, 8 AM – 11:30 AM CDT | |||||
| Abstract Number: | TPS7579 | |||||
| Presentation Title: | Phase 2, open-label study of CUDC-907 with and without rituximabin patients with relapsed/refractory MYC-altered diffuse large B celllymphoma | |||||
| Erivedge® Poster Presentations: | ||||||
| Date/Time: | Poster Session: Saturday, June 4, 1 PM – 4:30 PM CDT | |||||
| Poster Discussion Session: Saturday, June 4, 4:45 PM – 6 PM CDT | ||||||
| Abstract Number: | 9509 | |||||
| Presentation Title: | Mikie: A randomized, double-blinded, regimen-controlled, phase 2study to assess the efficacy and safety of two different vismodegib(VISMO) regimens in patients (pts) with multiple basal cellcarcinomas (BCCs) | |||||
| Date/Time: | Saturday, June 4, 1 PM – 4:30 PM CDT | |||||
| Abstract Number: | 9532 | |||||
| Presentation Title: | Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), inadvanced basal cell carcinoma (aBCC): STEVIE study primaryanalysis in 1215 patients (pts) | |||||
About Curis, Inc.Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exercised options to exclusively license oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]Source: Curis, Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RROCKET Burns 50% of Its Supply to Fuel Growth and Investor Confidence
- PMD Device Solutions Publishes 2023 Annual Report
- Vantage Drilling International Ltd. Schedules First Quarter 2024 Earnings Release Date and Conference Call
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
